Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacogenetic-Based Dosing of Irinotecan, Oxaliplatin, and Capecitabine in Advanced Small Bowel Adenocarcinoma
NCT00433550Phase 2Completed
- Sponsor
- Cancer and Leukemia Group B
- Start
- May 2007
- Primary completion
- Dec 2014
- Modality
- Nanoparticles, Monoclonal Antibodies, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label trial of capecitabine, irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab and oxaliplatin in small intestine adenocarcinoma (SBA) (3 arms), sponsored by Cancer and Leukemia Group B. Primary endpoint: Confirmed Tumor Response Rate (Proportion of Participants With Complete Response) at 36 weeks. Started May 2007; status: completed.
02
Drugs
capecitabineirinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumaboxaliplatin
03
Conditions
small intestine adenocarcinoma (SBA)
Beyond the preview
Go deeper on NCT00433550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00433550.